



(12) Translation of
European patent specification

(11) NO/EP 2694107 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/395 (2006.01)
A61P 17/00 (2006.01)
A61P 29/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.01.28
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.08.22
(86)	European Application Nr.	12765366.5
(86)	European Filing Date	2012.04.02
(87)	The European Application's Publication Date	2014.02.12
(30)	Priority	2011.04.01, US, 201161470538 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	XBiotech, Inc, 1055 West Hastings Street, Suite 300, Vancouver, British Columbia V6E 2E9, Canada
(72)	Inventor	SIMARD, John, 8201 East Riverside Drive Bldg 4 Suite 100, Austin, TX 78744, USA
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54) Title **TREATMENT FOR DERMATOLOGICAL PATHOLOGIES**

(56) References
Cited: WO-A2-2012/034039, US-A- 5 959 085, US-A1- 2002 022 720, US-A1- 2009 291 081, US-A1-
2009 298 096, US-A1- 2010 047 239, WO-A1-95/24917, YOST JOHN ET AL: "The role of TNF
inhibitors in psoriasis therapy: new implications for associated comorbidities.", F1000 MEDICINE
REPORTS 2009, vol. 1, 2009, XP002728711, ISSN: 1757-5931, BONIFATI C ET AL: "IL-1alpha,
IL-1beta and psoriasis: Conflicting results in the literature. Opposite behaviour of the two
cytokines in lesional or non-lesional extracts of whole skin", JOURNAL OF BIOLOGICAL
REGULATORS AND HOMEOSTATIC AGENTS, vol. 11, no. 4, October 1997 (1997-10), pages
133-136, XP009179746, ISSN: 0393-974X, GONZALEZ-LOPEZ M A ET AL: "New-onset
psoriasis following treatment with the interleukin-1 receptor antagonist anakinra", BRITISH
JOURNAL OF DERMATOLOGY, vol. 158, no. 5, May 2008 (2008-05), pages 1146-1148,
XP002728713, ISSN: 0007-0963, HITOSHI MIZUTANI ET AL.: 'Endogenous neutralizing anti-IL-
1 a autoantibodies in inflammatory skin diseases: possible natural inhibitor for over expressed
epidermal IL-1' JOURNAL OF DERMATOLOGICAL SCIENCE vol. 20, no. 1, 1999, pages 63 -
71, XP002995948, DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE
(NLM), BETHESDA, MD, US; May 2015 (2015-05), COLEMAN KYLE M ET AL: "Open-Label
Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1[alpha], for the

Treatment of Psoriasis.", XP009188541, Database accession no. NLM25715176, DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; June 2015 (2015-06), CARRASCO DANIEL ET AL: "An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity.", XP009188540, Database accession no. NLM26091380 & CARRASCO DANIEL ET AL: "An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity.", JOURNAL OF DRUGS IN DERMATOLOGY : JDD JUN 2015, vol. 14, no. 6, June 2015 (2015-06), pages 560-564, ISSN: 1545-9616, US-A1- 2010 221 179

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 1.** Anti-IL-1 α -antistoff for anvendelse i behandling av psoriasis vulgaris eller akne vulgaris.
- 2.** Anti-IL-1 α -antistoffet for anvendelse ifølge krav 1, hvori anti-IL-1 α -antistoffet er et monoklonalt antistoff.
- 3.** Anti-IL-1 α -antistoffet for anvendelse ifølge krav 2, hvori det monoklonale antistoffet er et IgG1.
- 4.** Anti-IL-1 α -antistoffet for anvendelse ifølge krav 2 eller 3, hvori det monoklonale antistoffet er MABp1.